间质细胞
肝细胞癌
基质
医学
癌症研究
恶性肿瘤
肿瘤微环境
癌症
肿瘤细胞
免疫学
病理
内科学
免疫组织化学
作者
Zhuo Yu,Leaf Huang,Jianfeng Guo
标识
DOI:10.1016/j.jconrel.2024.01.050
摘要
Hepatocellular carcinoma (HCC), the most commonly diagnosed primary liver cancer, has become a leading cause of cancer-related death worldwide. Accumulating evidence confirms that the stromal constituents within the tumor microenvironment (TME) exacerbate HCC malignancy and set the barriers to current anti-HCC treatments. Recent developments of nano drug delivery system (NDDS) have facilitated the application of stroma-targeting therapeutics, disrupting the stromal TME in HCC. This review discusses the stromal activities in HCC development and therapy resistance. In addition, it addresses the delivery challenges of NDDS for stroma-targeting therapeutics (termed anti-stromal nanotherapeutics in this review), and provides recent advances in anti-stromal nanotherapeutics for safe, effective, and specific HCC therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI